Dermatologic Toxicities from Monoclonal Antibodies and Tyrosine Kinase Inhibitors against EGFR: Pathophysiology and Management

Table 3

Dermatologic toxicity reported with single agent EGFR inhibitor therapy.

	Any grade (%)	Grade 3 and 4 (%)
Cetuximab [54, 55]	80–86	5–18
Panitumumab [56]	90	14
Erlotinib [11, 57]	75–79	5–10
Gefitinib [58]	62–75	Up to 4
Lapatinib [59]	27	1